Loading
A phase 3 trial testing KC1036 in oesophageal cancer, now recruiting.
A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Oesophageal Cancer is a phase 3 interventional study registered as NCT06194734, led by Beijing Konruns Pharmaceutical, and recruiting on the registry. Official title: A Randomised, Controlled, Open-label, Multicenter Phase III Study to Evaluate the Efficacy and Safety of KC1036 Versus Investigator's Choice of Chemotherapy as Third-line Therapy in Patients With Advanced Oesophageal Squamous Cell Carcinoma. Planned enrolment is 490 participants (estimated). The study started in 2024-02-05 and primary completion is expected in 2026-12-30. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Beijing Konruns Pharmaceutical, KC1036, Oesophageal squamous cell carcinoma, Oesophageal cancer.
Shares Beijing Konruns Pharmaceutical, KC1036.
Shares Beijing Konruns Pharmaceutical, KC1036.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/